Watch live 🔴

We are now starting our regular press briefing on EMA’s response to #COVID19 and other public health emergencies.

Don’t miss our tweets during the press briefing. Follow #EMAPresser.

🧵👇

https://www.youtube.com/watch?v=v42Biekaazc

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625842771130044418

COVID-19 still poses a significant burden on healthcare systems. The low uptake of #booster doses among vulnerable groups is a concern for #PublicHealth. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625843339017830400

We encourage elderly people, pregnant persons and immunocompromised patients who have not been revaccinated against #COVID with an #AdaptedVaccine, to do so.
#UnitedInProtection #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625843660649598976

We are discussing with international partners criteria and the process for an update of the #COVID19Vaccines. 💉
Vaccination campaigns could take place primarily once a year and at the start of the winter❄️. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844608402849793

The assessment of #COVID19Vaccine HIPRA 💉 is progressing, and we hope to conclude it very soon. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844808404049920

We collaborate closely with @WHO to enable access to safe and effective vaccines in many countries around the 🌍. #UnitedInProtection #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844973110235138

EMA is in contact with developers of mucosal #COVID19vaccines. We are ready to discuss emerging data from the vaccines that have already been deployed in India 🇮🇳 and China 🇨🇳. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844975073214472

We are evaluating an #RSV vaccine for older adults with a possible recommendation in the next months.
There is a need to better protect vulnerable groups against respiratory viruses 🦠 that might cause disease waves in winter. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845192136720385